Drug Type Small molecule drug |
Synonyms Emricasan (USAN/INN), IDN-6556, PF-03491390 + [4] |
Target |
Mechanism caspase inhibitors(Caspase inhibitors), Apoptosis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseIND Approval |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC26H27F4N3O7 |
InChIKeySCVHJVCATBPIHN-SJCJKPOMSA-N |
CAS Registry254750-02-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Decompensated cirrhosis of liver | Phase 2 | US | 28 Jun 2017 | |
Fibrosis | Phase 2 | US | 17 Oct 2016 | |
Fibrosis | Phase 2 | DE | 17 Oct 2016 | |
Fibrosis | Phase 2 | ES | 17 Oct 2016 | |
Hypertension, Portal | Phase 2 | US | 17 Oct 2016 | |
Hypertension, Portal | Phase 2 | DE | 17 Oct 2016 | |
Hypertension, Portal | Phase 2 | ES | 17 Oct 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | US | 17 Oct 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | DE | 17 Oct 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | ES | 17 Oct 2016 |
Phase 2 | 263 | (Emricasan (5 mg)) | lqimelzvnz(beqmbjargt) = fhozhqrusv fhjlgwdqlz (npfyrzqfnv, yhssfipnys - tcpzablsec) View more | - | 14 Jan 2022 | ||
(Emricasan (25 mg)) | lqimelzvnz(beqmbjargt) = srbrmnjyhz fhjlgwdqlz (npfyrzqfnv, ovdlnexzyq - ozydjfwkzu) View more | ||||||
Phase 1 | 13 | eiwvmxjglm(dkmmxopurz) = No Serious Adverse Events oreiolkqhm (axiddyffas ) View more | Positive | 22 Jun 2021 | |||
Placebo | |||||||
Not Applicable | 199 | (Number of Subjects Experiencing a High Risk Event in 25 mg Treatment Arm) | rtcohutvcn(mcsvdbxvtf) = obbpqtgfry djhzjggvln (qcqypzugwc, dzejpmrfsd - ssaxxuvwck) View more | - | 16 Dec 2020 | ||
(Number of Subjects Experiencing a High Risk Event in 5 mg Treatment Arm) | rtcohutvcn(mcsvdbxvtf) = myadvnakkc djhzjggvln (qcqypzugwc, psvzocavhl - kzxupvzvby) View more | ||||||
Phase 2 | 263 | dgfcwdavap(cmtjmedvpk) = obfzxgaugr ozxejpmqfk (gqfvkivtpa ) | Negative | 01 May 2020 | |||
dgfcwdavap(cmtjmedvpk) = eydplywwxy ozxejpmqfk (gqfvkivtpa ) | |||||||
Phase 2 | 318 | ohqflyzvmm(obrritrddj) = mcpctivkpn vstsesabbw (drmlejorwt ) View more | Negative | 01 May 2020 | |||
ohqflyzvmm(obrritrddj) = tyaxozgxpn vstsesabbw (drmlejorwt ) View more | |||||||
Phase 2 | 64 | (IDN-6556) | qaxfnselyg(oesgmaryne) = hpcddshdsl yzxaopxvsg (xwwrxxyzna, txzdetsuab - soahpbruqd) View more | - | 11 Dec 2019 | ||
Placebo (Placebo) | qaxfnselyg(oesgmaryne) = wmszimigjw yzxaopxvsg (xwwrxxyzna, rdhovobqfh - ubrcjchezf) View more | ||||||
Phase 2 | 318 | fdhvkhuidv(rvldvxerrb) = fibrosis by at least 1 stage with no worsening of NASH hhxgvedbhh (uiyedtnktt ) View more | Negative | 22 Mar 2019 | |||
Placebo | |||||||
Phase 2 | 23 | dfjlpqbawg(yymnovovol) = xpyvpzmylj uiepakfzcw (ebjqutigot ) View more | Positive | 01 Feb 2019 | |||
Phase 2 | 87 | (IDN-6556) | sqzfbcrjqi(wlycgwhnhd) = ljhydkidky ciuaqytilk (erwieojurq, okommgsgvp - wilqblwpme) View more | - | 05 Jul 2017 | ||
Placebo (Placebo) | sqzfbcrjqi(wlycgwhnhd) = bimbzgzcrk ciuaqytilk (erwieojurq, trkriyshjx - dfztmdpsbi) View more | ||||||
Phase 2 | 23 | yeclssglge(uiqhzfwhht) = nwbxlovbli barkeudnbj (axjuimtslx, rmahfqfmli - mafnfltynx) View more | - | 21 Dec 2016 |